# US 2015/0104459 A1 · Compositions and Methods for the Therapy and Diagnosis of Influenza

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0104459 A1
- Document ID: US20150104459A1
- Status: Published application
- Kind: A1
- Application number: 14/578,777
- Filed: 2014-12-22
- Published: 2015-04-16
- Earliest claimed: 2011-02-14
- Applicants: Theraclone Sciences, Inc.
- Inventors: Andres G. Grandea, III; Gordon King; Thomas C. Cox; Ole Olsen; Jennifer Mitcham; Matthew Moyle; Phil Hammond
- Web page: https://patentgrep.com/patent/US20150104459A1

## CPC

- C07K 16/108: Orthomyxoviridae (F), e.g. influenza virus
- A61K 39/42: viral
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/16: for influenza or rhinoviruses
- G01N 33/54306: {Solid-phase reaction mechanisms}
- G01N 33/56983: {Viruses}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/51: Complete heavy chain or Fd fragment, i.e. VH + CH1
- C07K 2317/515: Complete light chain, i.e. VL + CL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- G01N 2333/11: Orthomyxoviridae, e.g. influenza virus
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention provides compositions, vaccines, and methods for diagnosing, treating, and preventing influenza infection using a combination of antibodies raised against the influenza hemagglutinin and the matrix 2 ectodomain polypeptides.

## Claims

### Claim 1

A composition comprising:
(a) an isolated human antibody or antigen-binding fragment thereof that specifically binds to an epitope of the hemagglutinin (HA) glycoprotein of an influenza virus; and
(b) an isolated human monoclonal antibody or antigen-binding fragment thereof that specifically binds to an epitope in the extracellular domain of the matrix 2 ectodomain (M2e) polypeptide of an influenza virus.

### Claim 2 (depends on 1)

The composition of claim 1, wherein said isolated human monoclonal antibody or antigen-binding fragment thereof that specifically binds an epitope of the M2e polypeptide is selected from the group consisting of:
(a) an antibody or antigen-binding fragment thereof comprising a heavy chain variable (VH) domain and a light chain variable (VL) domain, wherein the VH domain and the VL domain each comprise three complementarity determining regions 1 to 3 (CDR1-3), and wherein each CDR comprises the following amino acid sequences:
VH CDR1: SEQ ID NOs: 72, 103, 179, 187, 203, 211, 228, 252, 260, 268, 284, 293, or 301;
VH CDR2: SEQ ID NOs: 74, 105, 180, 188, 204, 212, 229, 237, 253, 261, 269, 285, or 294;
VH CDR3 SEQ ID NOs: 76, 107, 181, 189, 197, 205, 213, 230, 238, 254, 262, 270, 286, or 295;
VL CDR1: SEQ ID NOs: 59, 92, 184, 192, 208, 192, 233, 241, 265, or 273;
VL CDR2: SEQ ID NOs: 61, 94, 185, 193, 209, 217, 226, 234, 258, 274, or 282; and
VL CDR3: SEQ ID NOs: 63, 96, 186, 194, 210, 218, 243, 259, 267, 275, 291, or 300; and
(b) an antibody or antigen-binding fragment thereof comprising a heavy chain variable (VH) domain and a light chain variable (VL) domain, wherein the VH domain and the VL domain each comprise three complementarity determining regions 1 to 3 (CDR1-3), and wherein each CDR comprises the following amino acid sequences:
VH CDR1: SEQ ID NOs: 109, 112, 182, 190, 206, 214, 239, 255, 263, 271, 287, 296, or 304;
VH CDR2: SEQ ID NOs: 110, 113, 183, 191, 207, 215, 232, 240, 256, 264, 272, 288, or 297;
VH CDR3 SEQ ID NOs: 76, 107, 181, 189, 197, 205, 213, 230, 238, 254, 262, 270, 286, or 295;
VL CDR1: SEQ ID NOs: 59, 92, 184, 192, 208, 192, 223, 241, 265, or 273;
VL CDR2: SEQ ID NOs: 61, 94, 185, 193, 209, 217, 226, 234, 258, 274, or 282; and
VL CDR3: SEQ ID NOs: 63, 96, 186, 194, 210, 218, 243, 259, 267, 275, 291, or 300.

### Claim 3 (depends on 1)

The composition of claim 1, wherein said isolated human antibody that specifically binds an epitope of the HA glycoprotein comprises a heavy chain variable region (VH) domain and a light chain variable (VL) domain, wherein the VH domain and the VL domain each comprise three complementarity determining regions 1 to 3 (CDR1-3), and wherein each CDR comprises the following amino acid sequences:
VH CDR1: SEQ ID NOs: 247, 571, 586, 597, 603, 609, 615, 627, 633, 637, 643, 649, 658, 664, 670, 303, 251, 242, or 222;
VH CDR2: SEQ ID NOs: 248, 572, 587, 592, 598, 604, 610, 616, 628, 634, 638, 644, 650, 655, 659, 665, 671, 306, 249, 307, or 221;
VH CDR3: SEQ ID NOs: 568, 573, 588, 593, 599, 605, 611, 617, 629, 635, 639, 645, 651, 656, 660, 666, 672, 725, 246, 290, or 220;
VL CDR1: SEQ ID NOs: 569, 574, 577, 580, 583, 589, 594, 612, 618, 621, 624, 640, 646, 652, 661, 667, 285, 289, 245, 224, or 219;
VL CDR2: SEQ ID NOs: 570, 575, 578, 581, 584, 590, 595, 601, 607, 613, 619, 622, 625, 631, 653, 662, 668, 305, 223, or 231;
VL CDR3: SEQ ID NOs: 289, 576, 579, 582, 585, 591, 596, 602, 608, 614, 620, 623, 626, 632, 636, 642, 648, 654, 657, 663, 669, 308, 250, 227, or 280.

### Claim 4 (depends on 1)

The composition of claim 1, wherein said epitope of the HA glycoprotein is GVTNKVNSIIDK (SEQ ID NO: 198), GVTNKVNSIINK (SEQ ID NO: 283), GVTNKENSIIDK (SEQ ID NO: 202), GVTNKVNRIIDK (SEQ ID NO: 201), GITNKVNSVIEK (SEQ ID NO: 281), GITNKENSVIEK (SEQ ID NO: 257), GITNKVNSIIDK (SEQ ID NO: 225), and KITSKVNNIVDK (SEQ ID NO: 216).

### Claim 5 (depends on 1)

The composition of claim 1, wherein said epitope of the M2e polypeptide is a discontinuous epitope.

### Claim 6 (depends on 1)

The composition of claim 1, wherein said epitope of the M2e polypeptide comprises,
a) the amino acid at positions 2, 5, and 6 of MSLLTEVETPTRNEWGCRCNDSSD (SEQ ID NO: 1); or
b) the amino acid at positions 2, 5, and 6 of SLLTEV (SEQ ID NO: 42).

### Claim 7 (depends on 1)

The composition of claim 1 comprising:
(a) an isolated human anti-HA antibody, or an antigen-binding fragment thereof, comprising a heavy chain variable region (VH) domain, wherein the VH domain comprises the following amino acid sequences: SEQ ID NOs 309, 313, 317, 321, 325, 329, 333, 337, 341, 345, 349, 353, 357, 361, 365, 369, 373, 377, 381, 385, 389, 393, 397, 401, 405, 409, 199, 417, 423, 429, 435, 441, 447, 453, 459, 465, 471, 477, 483, 489, 495, 501, 507, 513, 519, 525, 531, 537, 543, 550, 556, or 562, and a light chain variable (VL) domain, wherein the VL domain comprises the following amino acid sequences: SEQ ID NOs 310, 314, 318, 322, 326, 330, 334, 338, 342, 346, 350, 354, 358, 362, 366, 370, 374, 378, 382, 386, 390, 394, 398, 402, 406, 410, 414, 420, 426, 432, 438, 444, 450, 456, 462, 468, 474, 480, 486, 492, 498, 504, 510, 516, 522, 528, 534, 540, 547, 553, 559, or 565; and
(b) an isolated anti-matrix 2 ectodomain (M2e) antibody, or antigen-binding fragment thereof, comprising a heavy chain variable (VH) domain, wherein the VH domain comprises the following amino acid sequences: SEQ ID NOs 44, 277, 276, 50, 236, 235, 116, 120, 124, 128, 132, 136, 140, 144, 148, 152, 156, 160, 164, 168, 172, or 176, and a light chain variable (VL) domain, wherein the VL domain comprises the following amino acid sequences: SEQ ID NOs 46, 292, 52, 118, 122, 126, 130, 134, 138, 142, 146, 150, 154, 158, 162, 166, 170, or 178.

### Claim 8 (depends on 1)

A multivalent vaccine composition comprising the composition of claim 1.

### Claim 9 (depends on 1)

A pharmaceutical composition comprising the composition of claim 1 and a pharmaceutical carrier.

### Claim 10 (depends on 9)

A method for stimulating an immune response in a subject, comprising administering to the subject the composition of claim 9.

### Claim 11 (depends on 9)

A method for the treatment of an influenza virus infection in a subject in need thereof, comprising administering to said subject the composition of claim 9.

### Claim 12 (depends on 11)

The method of claim 11, wherein the subject has been exposed to an influenza virus.

### Claim 13 (depends on 12)

The method of claim 12, wherein the subject has not be diagnosed with an influenza infection.

### Claim 14 (depends on 8)

A method for the prevention of an influenza virus infection in a subject in need thereof, comprising administering to said subject the vaccine of claim 8, prior to exposure of said subject to an influenza virus.

### Claim 15 (depends on 11)

The method of claim 11, wherein the method further comprises administering an anti-viral drug, a viral entry inhibitor or a viral attachment inhibitor.

### Claim 16 (depends on 15)

The method of claim 15, wherein said anti-viral drug is a neuraminidase inhibitor, a HA inhibitor, a sialic acid inhibitor or an M2 ion channel.

### Claim 17 (depends on 16)

The method of claim 16, wherein said M2 ion channel inhibitor is amantadine or rimantadine.

### Claim 18 (depends on 16)

The method of claim 16, wherein said neuraminidase inhibitor is zanamivir or oseltamivir phosphate.

### Claim 19 (depends on 11)

The method of claim 11, further comprising administering a second anti-Influenza A antibody.

### Claim 20 (depends on 19)

The method of claim 19, wherein said antibody is administered prior to or after exposure to Influenza virus.

### Claim 21 (depends on 12)

The method of claim 12, wherein the subject is at risk of contracting an influenza infection.

### Claim 22 (depends on 11)

The method of claim 11, wherein said composition is administered at a dose sufficient to promote viral clearance or eliminate influenza infected cells.

### Claim 23 (depends on 1)

A method for determining the presence of an Influenza virus infection in a subject, comprising the steps of:
(a) contacting a biological sample obtained from the subject with the antibody of claim 1;
(b) detecting an amount of the antibody that binds to the biological sample; and
(c) comparing the amount of antibody that binds to the biological sample to a control value, and therefrom determining the presence of the Influenza virus in the subject.

### Claim 24 (depends on 1, 23)

The method of claim 23, wherein the control value is determined by contacting a control sample obtained from the subject with the antibody according to claim 1 and detecting an amount of the antibody that binds to the control sample.
